News
Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations
Moderna's stock price fell by up to 25% despite a cancer vaccine that reduced the risk of melanoma recurrence or death by 42%, as market expectations were very high. The news appeared on BeInCrypto and was shared via BeInCrypto.